JCR's Gene Therapy Shows Promise for Brain Disorders

HYOGO, Japan – May 18, 2026 – A novel gene therapy platform is showing remarkable potential to overcome one of the most formidable barriers in modern medicine: safely and effectively delivering treatments to the human brain. At the recent American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, JCR Pharmaceuticals presented a wealth of preclinical data on its JUST-AAV technology, a system designed to act as a highly specialized courier for genetic medicines. The findings, which demonstrate targeted delivery to the central nervous system (CNS) with significantly reduced off-target effects, suggest a potential paradigm shift for treating a host of devastating neurological conditions.

The data, presented alongside supportive findings from collaborator Alexion, AstraZeneca Rare Disease, generated significant interest at the Boston conference. It paints a picture of a technology that could unlock new therapeutic avenues for rare, inherited disorders that have long been considered intractable.

A Smarter Delivery System for Gene Therapy

The central challenge for any gene therapy aimed at neurological disease is the blood-brain barrier (BBB), a highly selective membrane that protects the brain from toxins and pathogens but also blocks most therapeutic drugs. Conventional adeno-associated virus (AAV) vectors, the workhorses of gene therapy, often struggle to cross this barrier in sufficient quantities and can accumulate in the liver, leading to potential toxicity concerns.

JCR's JUST-AAV platform tackles these problems head-on. The technology involves engineering the AAV capsid—the virus's outer protein shell—by inserting miniaturized antibodies that act like molecular keys. These antibodies are designed to bind to specific receptors, such as the transferrin receptor (TfR), which are abundant on the cells of the BBB and help transport essential molecules into the brain. By hijacking this natural transport system, JUST-AAV vectors can effectively ferry their genetic payload into the CNS.

"The presented preclinical results demonstrate that JCR’s novel capsid platform is able to deliver therapeutic agents to the central nervous system more efficiently than conventional AAV9, while reducing liver accumulation," said Hiroyuki Sonoda, Ph.D., President and Chief Scientific Officer at JCR Pharmaceuticals, in a statement. "These data represent an advancement toward potential new treatment options for previously challenging CNS diseases."

Furthermore, the platform incorporates additional capsid modifications designed to actively detarget the liver. Research data indicates this dual approach is highly effective. In preclinical models, brain-targeting JUST-AAV vectors achieved a 77-fold higher gene expression in the brain compared to the standard AAV9 vector, while simultaneously reducing liver accumulation by a staggering 99%. This ability to increase the "on-target" dose in the brain while minimizing "off-target" exposure in the liver is a critical step toward improving both the safety and efficacy of systemic gene therapy.

Preclinical Proof Offers Hope for Devastating Diseases

The true potential of the JUST-AAV platform was vividly illustrated in studies targeting specific, life-threatening lysosomal storage disorders. These diseases result from genetic defects that lead to the buildup of toxic materials within cells, causing progressive and severe damage, particularly to the nervous system.

For GM1 gangliosidosis, a rapidly progressing neurodegenerative disorder with no approved cure, researchers used a JUST-AAV vector to deliver a gene encoding a BBB-penetrating therapeutic enzyme. When administered intravenously to a mouse model of the disease, the therapy resulted in high levels of the corrective enzyme in the brain. This led to a marked reduction in the toxic accumulation of GM1 ganglioside, improved neurological function, and, most strikingly, a significant extension of survival. The success of a human-specific construct in a humanized mouse model provides what the company calls "strong translational support" for moving toward human clinical trials.

Equally compelling results were presented for Neuronal Ceroid Lipofuscinosis (NCL), also known as Batten disease, a group of fatal neurodegenerative disorders that primarily affect children. In mouse models of two forms, CLN1 and CLN2, a single systemic injection of the corresponding JUST-AAV therapy yielded profound benefits. Compared to untreated mice or those receiving conventional AAV9, the mice treated with JUST-AAV had lifespans almost comparable to healthy animals. Post-mortem analysis confirmed high levels of the needed enzyme in the brain, reduced neuroinflammation, and preservation of motor function and even retinal thickness, addressing the vision loss that is a hallmark of the disease.

Strategic Validation Through Big Pharma Partnership

The scientific promise of the JUST-AAV platform is powerfully underscored by a significant strategic alliance with Alexion, AstraZeneca's rare disease group. Building on two prior collaborations, the companies entered into a license agreement in July 2025, granting Alexion access to JCR's proprietary capsids for up to five of its own genomic medicine programs.

Under the agreement, JCR is set to receive an upfront payment and is eligible for up to $825 million in research, development, and sales milestones, in addition to royalties. This level of investment from a global leader in rare diseases serves as a major external validation of the technology's potential.

At the same ASGCT meeting, Alexion presented its own preclinical data using a TfR-targeted JUST-AAV capsid. Their findings in both mouse and non-human primate models corroborated JCR's results, showing broad CNS biodistribution, a favorable brain-to-liver exposure ratio, and good tolerability. This parallel work not only reinforces the platform's robustness but also highlights the collaborative momentum accelerating its path toward the clinic. The partnership effectively combines JCR's innovative delivery technology with Alexion's deep expertise in developing and commercializing therapies for rare diseases, creating a synergistic force aimed at tackling some of medicine's toughest challenges. This strategic alignment is a clear signal to the industry that the JUST-AAV platform is not just a scientific curiosity but a commercially viable asset with the potential to anchor a new generation of treatments.

The path from preclinical research to an approved therapy is long and fraught with challenges. However, the comprehensive data package presented at ASGCT, combining elegant molecular engineering with dramatic efficacy in disease models and backed by a formidable industry partnership, positions the JUST-AAV platform as one of the most promising next-generation technologies in the gene therapy space. For families affected by devastating neurodegenerative disorders, this progress represents a crucial and tangible source of hope.